A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo

摘要

A genome-wide CRISPR/Cas9 screen identifies vulnerabilities to metformin in U251 cells. a Schematic of genome-wide CRISPR/Cas9 screening for candidate genes that are synergistic with metformin. b The scores for each gene in the control (T0) and metformin (T18) treatment groups. Orange dots represent the genes synergistic with metformin. c Pathway enrichment analysis of the genes identified in the screen using the KEGG database. d Differences in sgRNA counts for CDK1, CDK4, and CDK6 between T0 and T18